Last reviewed · How we verify

NCT04906564

RNF213 Variants and Collateral Vessels in Moyamoya Disease

Completed Last updated 17 February 2022
What this trial tests

trial testing Identification of genetic variants in Moyamoya Disease in 300 participants. Completed in 30 June 2021.

Timeline
1 January 2019
Primary endpoint
30 June 2021
30 June 2021

Quick facts

Lead sponsorBeijing Tiantan Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment300
Start date1 January 2019
Primary completion30 June 2021
Estimated completion30 June 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 4 to 60, any sex, with Moyamoya Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to detect the association between RNF213 variants and collateral vessels in patients with moyamoya disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Identification of genetic variants

Trials testing the same drug.

Other recruiting trials for Moyamoya Disease

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing